ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 239,99
0,17%
Dow Jones
39 882,13
0,82%
DAX
18 869,36
0,78%
Brent Oil
82,67
0,15%
Bitcoin
66 240,08
7,63%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Marker Therapeutics Inc (MRKR)

  7. Marker Therapeutics Inc (MRKR) Actualités

MRKR

Marker Therapeutics (MRKR)

Marker Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MRKR
DateHeureSourceTitreSymboleSociété
08/04/202413h00GlobeNewswire Inc.Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies NASDAQ:MRKRMarker Therapeutics Inc
25/03/202422h45GlobeNewswire Inc.Marker Therapeutics Reports Year-End 2023 Corporate and Financial ResultsNASDAQ:MRKRMarker Therapeutics Inc
22/03/202417h30GlobeNewswire Inc.Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceNASDAQ:MRKRMarker Therapeutics Inc
01/03/202414h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
22/01/202413h30GlobeNewswire Inc.Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601NASDAQ:MRKRMarker Therapeutics Inc
08/01/202414h24GlobeNewswire Inc.Marker Therapeutics Announces Clinical Program Updates and Pipeline PrioritizationNASDAQ:MRKRMarker Therapeutics Inc
21/12/202317h00GlobeNewswire Inc.Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”NASDAQ:MRKRMarker Therapeutics Inc
11/12/202313h00GlobeNewswire Inc.Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T RelapseNASDAQ:MRKRMarker Therapeutics Inc
09/11/202323h00GlobeNewswire Inc.Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:MRKRMarker Therapeutics Inc
09/11/202322h31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRKRMarker Therapeutics Inc
11/09/202313h00GlobeNewswire Inc.Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T RelapseNASDAQ:MRKRMarker Therapeutics Inc
30/08/202314h00GlobeNewswire Inc.Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:MRKRMarker Therapeutics Inc
14/08/202322h30GlobeNewswire Inc.Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:MRKRMarker Therapeutics Inc
07/08/202313h00GlobeNewswire Inc.Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf ProgramNASDAQ:MRKRMarker Therapeutics Inc
26/07/202313h00GlobeNewswire Inc.Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023NASDAQ:MRKRMarker Therapeutics Inc
10/07/202313h00GlobeNewswire Inc.European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML PatientsNASDAQ:MRKRMarker Therapeutics Inc
05/07/202322h22Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MRKRMarker Therapeutics Inc
26/06/202313h15Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:MRKRMarker Therapeutics Inc
26/06/202313h00GlobeNewswire Inc.Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent AdministrationNASDAQ:MRKRMarker Therapeutics Inc
12/06/202313h00GlobeNewswire Inc.Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical TrialNASDAQ:MRKRMarker Therapeutics Inc
31/05/202312h30GlobeNewswire Inc.Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma CellsNASDAQ:MRKRMarker Therapeutics Inc
15/05/202322h16Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:MRKRMarker Therapeutics Inc
12/05/202300h11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:MRKRMarker Therapeutics Inc
08/05/202313h30GlobeNewswire Inc.Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical OfficerNASDAQ:MRKRMarker Therapeutics Inc
01/05/202313h30GlobeNewswire Inc.Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™NASDAQ:MRKRMarker Therapeutics Inc
28/04/202322h12Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:MRKRMarker Therapeutics Inc
28/04/202322h12Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:MRKRMarker Therapeutics Inc
22/03/202313h21Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:MRKRMarker Therapeutics Inc
22/03/202313h10GlobeNewswire Inc.Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial ResultsNASDAQ:MRKRMarker Therapeutics Inc
03/01/202315h01Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:MRKRMarker Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:MRKR

Dernières Valeurs Consultées

NASDAQ
FYTZYX
Interest Rate Hedge and ...
BIT
P1NAH9
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés